AW
RCUS icon

Ankerstar Wealth’s Arcus Biosciences RCUS Stock Holding History

Ankerstar Wealth’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173 Sell
8
-3
-27% -$65 ﹤0.01% 868
2025
Q4 		$262 Buy
+11
New +$224 ﹤0.01% 824

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ankerstar Wealth's RCUS Position: Q1 2026 in Review

Ankerstar Wealth reduced its Arcus Biosciences (RCUS) stake by 27% in Q1 2026, selling an estimated $65 and leaving 8 shares worth $173. The position accounts for ﹤0.01% of the portfolio, ranked #868.

Ankerstar Wealth first reported a position in RCUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $262 in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Ankerstar Wealth held 8 shares of Arcus Biosciences worth $173 as of Q1 2026.
  • Ankerstar Wealth sold 3 Arcus Biosciences shares in Q1 2026, an estimated $65.
  • Arcus Biosciences made up ﹤0.01% of Ankerstar Wealth's portfolio in Q1 2026, its #868 holding.
  • Ankerstar Wealth first reported a position in Arcus Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Ankerstar Wealth's Arcus Biosciences position peaked at $262 in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Ankerstar Wealth's 13F filing for Q1 2026, filed 14 May 2026.